Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis
Researchers have developed and validated a tool called a nomogram to predict the likelihood of disease progression to generalized MG in patients with ocular myasthenia gravis (OMG) over a period of 1-2 years. The nomogram was constructed using data from 501 patients treated in Chinese hospitals. It incorporates five variables including sex, onset age, nerve stimulation findings, antibody test results, and thymic status. The nomogram showed good discrimination and calibration, accurately estimating the probability of OMG converting to generalized MG. It can assist neurologists in identifying patients who may benefit from specific treatments and clinical trials aimed at modifying the risk of disease progression.